Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 5 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 2 |
| Introduction | 10 | 1 |
| Market Overview | 11 | 16 |
| Introduction | 11 | 1 |
| HCV Classification | 11 | 1 |
| HCV Genome | 12 | 1 |
| HCV Diagnosis | 13 | 1 |
| HCV Treatment Goals | 13 | 2 |
| Current HCV Treatment Options | 15 | 1 |
| Pegylated Interferon-alpha + Ribavirin Combination Therapy | 15 | 1 |
| Protease Inhibitors (PI) + Pegylated Interferon-alpha + Ribavirin Combination Therapy | 16 | 1 |
| Future HCV Treatment Paradigm | 16 | 1 |
| Direct-acting Antiviral Therapy | 16 | 1 |
| Host-Targeting Antiviral Therapy | 17 | 1 |
| Novel Interferons | 17 | 1 |
| Global Hepatitis C Therapeutics Market | 18 | 1 |
| Revenue | 18 | 1 |
| Revenue Segmentation by Geography | 19 | 2 |
| Branded and Generic Product Share | 21 | 1 |
| Annual Cost of Therapy | 22 | 1 |
| Treatment Usage Pattern | 23 | 2 |
| Prevalence Population | 25 | 1 |
| Diagnosed Population | 25 | 1 |
| Treated Population | 25 | 1 |
| Market Trends | 26 | 1 |
| Geographic Landscape | 27 | 25 |
| The US | 27 | 1 |
| Revenue | 27 | 1 |
| Annual Cost of Therapy | 28 | 1 |
| Treatment Usage Pattern | 29 | 1 |
| Prevalence Population | 30 | 1 |
| Diagnosed Population | 30 | 1 |
| Treated Population | 31 | 1 |
| Top Five Countries of Europe | 31 | 1 |
| Revenue | 31 | 2 |
| Revenue by Country | 33 | 2 |
| Annual Cost of Therapy | 35 | 1 |
| Treatment Usage Pattern | 36 | 1 |
| Prevalence Population | 37 | 1 |
| Diagnosed Population | 37 | 1 |
| Treated Population | 37 | 1 |
| Japan | 38 | 1 |
| Revenue | 38 | 1 |
| Annual Cost of Therapy | 39 | 1 |
| Treatment Usage Pattern | 40 | 1 |
| Prevalence Population | 41 | 1 |
| Diagnosed Population | 41 | 1 |
| Treated Population | 41 | 1 |
| Other Markets | 42 | 1 |
| Australia | 42 | 1 |
| Epidemiology | 42 | 1 |
| Risk Factors | 42 | 1 |
| Market Trends | 42 | 1 |
| Clinical Trials | 43 | 3 |
| China | 46 | 1 |
| Epidemiology | 46 | 1 |
| Risk Factors | 47 | 1 |
| Market Trends | 48 | 1 |
| Clinical Trials | 49 | 1 |
| India | 49 | 1 |
| Epidemiology | 49 | 1 |
| Risk Factors | 50 | 1 |
| Market Trends | 50 | 1 |
| Clinical Trials | 51 | 1 |
| Pipeline Analysis | 52 | 28 |
| Research and Development Pipeline | 52 | 1 |
| Highlights from the International Liver Congress 2012, European Association for the Study of the Liver | 53 | 2 |
| Recently Launched | 55 | 1 |
| Incivek/Telavic/Incivo (telaprevir) | 55 | 1 |
| Class of Drug | 55 | 1 |
| Clinical Trials Results and Analysis | 55 | 3 |
| Revenue and Revenue Forecast | 58 | 1 |
| Victrelis | 58 | 1 |
| Class of Drugs | 58 | 1 |
| Clinical Trials Results and Analysis | 58 | 1 |
| Revenue and Revenue Forecast | 59 | 1 |
| Perspective on Incivek and Victrelis | 59 | 2 |
| Most Promising Molecules in Phase III | 61 | 1 |
| GS-7977 | 61 | 1 |
| Class of Drug | 61 | 1 |
| Clinical Trials Results and Analysis | 61 | 5 |
| Other Combination Trials in Progress | 66 | 1 |
| Expected Approval Timeline | 66 | 1 |
| BMS-790052 (daclatasvir) | 67 | 1 |
| Class of Drugs | 67 | 1 |
| Clinical Trials Results and Analysis | 67 | 1 |
| Other Combinations Trials in Progress | 67 | 1 |
| TMC-435 | 68 | 1 |
| Class of Drugs | 68 | 1 |
| Clinical Trials Results and Analysis | 68 | 1 |
| Other Combination Trials in Progress | 69 | 1 |
| Expected Approval Timeline | 69 | 1 |
| BI-201335 | 70 | 1 |
| Class of Drugs | 70 | 1 |
| Clinical Trials Results and Analysis | 70 | 2 |
| Other Combination Trials in Progress | 72 | 1 |
| Most Promising Molecules in Phase II | 73 | 1 |
| ABT-450 | 73 | 1 |
| Class of Drugs | 73 | 1 |
| Clinical Trials Results and Analysis | 73 | 1 |
| Other Combination Trials in Progress | 73 | 1 |
| GS-5885 | 74 | 1 |
| Class of Drugs | 74 | 1 |
| Clinical Trials Results and Analysis | 74 | 1 |
| Expected Approval Timeline | 74 | 1 |
| RG7128 (mericitabine) | 74 | 1 |
| Class of Drugs | 74 | 1 |
| Clinical Trials Results and Analysis | 74 | 1 |
| Other Combination Trials in Progress | 75 | 1 |
| Expected Approval Timeline | 75 | 1 |
| ACH-1625 | 75 | 1 |
| Class of Drugs | 75 | 1 |
| Clinical Trials Results and Analysis | 75 | 1 |
| Combination Therapy Development | 76 | 1 |
| With PEG-IFN and RBV | 76 | 1 |
| With RBV only | 77 | 1 |
| Without PEG-IFN and RBV | 78 | 2 |
| Competitive Landscape | 80 | 15 |
| Market Share Analysis | 80 | 1 |
| Competitive Profiling | 81 | 1 |
| Vertex Pharmaceuticals, Inc. | 81 | 1 |
| Company Overview | 81 | 1 |
| Future Prospects Hepatitis C | 81 | 1 |
| SWOT Analysis | 82 | 1 |
| Merck &Co., Inc. | 82 | 1 |
| Company Overview | 82 | 1 |
| Future Prospects Hepatitis C | 83 | 1 |
| SWOT Analysis | 83 | 1 |
| Gilead Sciences, Inc. | 84 | 1 |
| Company Overview | 84 | 1 |
| Future Prospects Hepatitis C | 84 | 1 |
| SWOT Analysis | 85 | 1 |
| Bristol-Myers Squibb Company | 85 | 1 |
| Company Overview | 85 | 1 |
| Future Prospects Hepatitis C | 85 | 1 |
| SWOT Analysis | 86 | 1 |
| Abbott Laboratories | 87 | 1 |
| Company Overview | 87 | 1 |
| Future Prospects Hepatitis C | 87 | 1 |
| SWOT Analysis | 88 | 1 |
| F. Hoffmann-La Roche Ltd. | 88 | 1 |
| Company Overview | 88 | 1 |
| Future Prospects Hepatitis C | 88 | 1 |
| SWOT Analysis | 89 | 1 |
| Johnson &Johnson/Tibotec BVBA | 89 | 1 |
| Company Overview | 89 | 1 |
| Future Prospects Hepatitis C | 90 | 1 |
| SWOT Analysis | 90 | 1 |
| Boehringer Ingelheim GmbH | 91 | 1 |
| Company Overview | 91 | 1 |
| Future Prospects Hepatitis C | 91 | 1 |
| SWOT Analysis | 91 | 1 |
| Novartis AG | 92 | 1 |
| Company Overview | 92 | 1 |
| Future Prospects Hepatitis C | 92 | 1 |
| SWOT Analysis | 92 | 1 |
| Achillion Pharmaceuticals, Inc. | 93 | 1 |
| Company Overview | 93 | 1 |
| Future Prospects Hepatitis C | 93 | 1 |
| SWOT Analysis | 93 | 1 |
| Idenix Pharmaceuticals, Inc. | 94 | 1 |
| Company Overview | 94 | 1 |
| SWOT Analysis | 94 | 1 |
| Strategic Consolidations | 95 | 11 |
| Deals by Year | 96 | 1 |
| Deals by Type | 97 | 1 |
| Deals by Value | 98 | 1 |
| Deals by Region | 99 | 1 |
| Mergers and Acquisitions | 100 | 1 |
| Major M&A Deals | 101 | 1 |
| Bristol-Myers Squibb Completes Acquisition of Inhibitex, Hepatitis C Drug Developer, for $2.5 billion | 101 | 1 |
| Gilead Sciences Completes Acquisition of Pharmasset for $11.2 billion | 101 | 1 |
| Licensing Agreements | 102 | 1 |
| Major Licensing Agreements | 103 | 1 |
| Enanta Pharma Enters Into Licensing Agreement with Novartis for Hepatitis C Program | 103 | 1 |
| Vertex Pharma Enters Into Licensing Agreement with Alios BioPharma for ALS-2200 and ALS-2158 | 103 | 1 |
| Partnerships | 104 | 1 |
| Major Partnership Deals | 105 | 1 |
| Merck Extends Co-Promotion Agreement with Roche for Victrelis | 105 | 1 |
| Teva Pharma Enters Into Co-Development Agreement with Cocrystal Discovery | 105 | 1 |
| Appendix | 106 | 8 |
| Market Definitions | 106 | 1 |
| Abbreviations | 106 | 1 |
| Bibliography | 107 | 1 |
| Research Methodology | 108 | 6 |
| Coverage | 108 | 1 |
| Secondary Research | 109 | 1 |
| Primary Research | 109 | 1 |
| Therapeutic Landscape | 110 | 1 |
| Epidemiology-based Forecasting | 110 | 2 |
| Market Size by Geography | 112 | 1 |
| Geographical Landscape | 113 | 1 |
| Pipeline Analysis | 113 | 1 |
| Competitive Landscape | 113 | 1 |
| Expert Panel Validation | 113 | 1 |
| Contact Us | 113 | 1 |
| Disclaimer | 113 | 1 |